Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus - AleCardio


The goal of the trial was to evaluate treatment with the peroxisome proliferator-activated receptor (PPAR) dual-agonist aleglitazar compared with placebo among type 2 diabetic patients hospitalized for an acute coronary syndrome. Aleglitazar is a dual agonist of PPAR-α and -γ receptors. The primary effect of PPAR-α activation is to improve plasma lipid profile, while the primary effect of PPAR-γ activation is to improve insulin sensitivity.